Growth Hormone Peptide Safety
Safety considerations for unapproved growth hormone-releasing peptides. Learn why caution is warranted with these research compounds.
Safety Overview
Most growth hormone-releasing peptides are not FDA approved and have limited human safety data. This page discusses general concerns.
Lack of Safety Data
| Peptide | FDA Status | Human Safety Studies |
|---|---|---|
| Ipamorelin | Not approved | Limited Phase 1/2 |
| CJC-1295 | Not approved | Very limited |
| GHRP-6 | Not approved | Pharmacology only |
| Sermorelin | Was approved | Established (historical) |
General GH-Related Concerns
When GH levels are elevated, potential concerns include:
Known GH-Related Effects
- Joint pain (arthralgia)
- Fluid retention and swelling
- Carpal tunnel syndrome
- Glucose intolerance
- Theoretical cancer concerns with elevated IGF-1
Unknown Long-Term Effects
- Chronic elevated GH effects not studied
- Cancer risk with long-term IGF-1 elevation
- Effects on heart structure
- Interaction with other conditions
Product Quality Concerns
Unregulated peptides may have:
- Unknown purity
- Contamination
- Incorrect labeling
- Degradation products
WADA Prohibition
All GH secretagogues are prohibited in sport as performance-enhancing drugs.
Safer Alternatives
If GH deficiency is suspected:
- Get proper medical evaluation
- Consider FDA-approved options (if indicated)
- Work with an endocrinologist
This safety information is for educational purposes. These peptides are not FDA-approved.
Disclaimer: This article is for educational purposes only and does not constitute medical advice. The information presented is based on current research but should not be used for diagnosis, treatment, or prevention of any disease. Always consult a qualified healthcare provider before making health decisions.